Company news
Assembly Biosciences, Inc. news in 2023
Assembly Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 9, 2023
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
November 9, 2023
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
November 7, 2023
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
November 7, 2023
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 16, 2023
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 10, 2023
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 1, 2023
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 18, 2023
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 8, 2023
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 16, 2023
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 20, 2023
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 6, 2023
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 22, 2023
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 3, 2023
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 17, 2023
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 21, 2023
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 14, 2023